Jim Mellon Announces Launch of New Book – Juvenescence: Investing in the Age of Longevity – Press Release by Biogerontology Research Foundation
Biogerontology Research Foundation
London, UK: Biogerontology Research Foundation Trustee Jim Mellon announces the publication of his newest book, Juvenescence: Investing in the Age of Longevity.
The book is a comprehensive summary of the emerging longevity industry, including profiles of longevity companies, investment opportunities, and aims to chart the major ideas of the geroscience’s thought-leaders and the vast implications this will have on economies and societies.
Often referred to as the British Warren Buffett, Billionaire Jim Mellon is well known for identifying major emerging trends before they become mainstream. Mellon made his wealth by investing in emerging markets throughout the 1990s. After many years of research and investing in the life science sector, Jim announced his vision for the emergence of the nascent longevity industry at Master Investor, one of the UK’s leading investor show in March of 2017, which was attended by over five thousand investors and entrepreneurs.
“The Biogerontology Research Foundation is proud to support what we feel will come to be seen as a landmark publication in the modern history of biogerontology. Jim has put an enormous amount of thought and effort into this new book, and has interviewed many of the field’s leading scientists in his research. The field of geroscience and the emerging longevity industry are both sure to prosper from very well-respected business personalities like Jim Mellon championing the longevity industry and projecting that it will become the world’s largest industry. Further, governments and policy makers should note the pressing need for a paradigm shift in medicine and healthcare away from ‘sick care’ toward comprehensive and disease-preventative healthspan extension. We are proud to have Jim as a Trustee of the Biogerontology Research Foundation and look forward to helping him lend mainstream credibility to the field and actionability to the dawning longevity industry” said Franco Cortese, Deputy Director & Trustee of the Biogerontology Research Foundation.
In 2012, Jim published his best-seller Cracking the Code, which summarized his vision for the future of the life science sector. In 2017, he announced his intention to focus much of his time and assets on the emerging longevity industry and make substantial investments into this area.
Jim and long-time co-author Al Chalabi toured many academic institutions, biopharmaceutical companies, and Silicon Valley tech companies to learn about the latest research and to understand the rapidly advancing field of longevity. Juvenescence highlights the technologies they deem the most likely to generate substantial longevity dividends and create sustainable and profitable industries. They travelled through the US and Europe, interviewing geroscience’s leading scientists and thought-leaders and provide an objective survey of their findings well as a detailed vision for the industry’s future and the most appropriate investment opportunities within the dawning longevity industry.
This is the cover of Juvenescence: Investing in the Age of Longevity by Jim Mellon and Al Chalabi
Credit: Jim Mellon & Al Chalabi
###
Earlier this year Jim Mellon announced the formation of Juvenescence Limited, a company investing in the longevity biotechnology. Since then the company announced investments in several high-profile longevity companies including Insilico Medicine, Inc, a Baltimore-based leader in artificial intelligence for drug discovery, biomarker development, and aging research.
About the Biogerontology Research Foundation:
The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.